Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Justin A. Budka et al.|Blood Cancer Discovery|2023Cited by 49
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Unknown|2024Cited by 0
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Unknown|2024Cited by 0
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Unknown|2024Cited by 0
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)Simone Filosto, Jason R. Westin, Saran Vardhanabhuti et al.|Unknown|2024Cited by 0